Consistent with the observation from rosiglitazone-treated adipose-specific Seipin knockout mice (Liu et al., 2014) and troglitazone-treated lipodystrophy patients (Arioglu et al., 2000), sWAT in our study showed a significant response to a PPARγ agonist. This evidence concerns the gene BSCL2 and lipodystrophy.